Bionor files first clinical trial application for BIOSKILL

(Oslo, Norway, 17 November 2015) Bionor Pharma ASA (OSE:BIONOR) today announced the submission of a clinical trial application (CTA) to the Danish Medicines Agency requesting approval to initiate BIOSKILL in Denmark. BIOSKILL (BIOnor Shock and KILL) will enroll patients internationally and further CTAs will be submitted to national medicines agencies in the coming months. BIOSKILL …

Read more

Results of the REDUC study Part A published in the journal PLoS Pathogens

(Oslo, Norway, 18 September 2015) Bionor Pharma ASA (Bionor) (OSE:BIONOR), a peptide vaccine company advancing a potential first therapeutic vaccine towards a functional cure for HIV, today announces the publication of the manuscript “The Depsipeptide Romidepsin Reverses HIV-1 Latency in vivo” in the peer-reviewed journal PLoS Pathogens. Ole Schmeltz Søgaard from Aarhus University Hospital in …

Read more

Bionor announces promising results from an interim analysis of the functional cure HIV study REDUC Part B

Indicating killing of reactivated HIV virus and reduction in latent viral reservoir when patients receive the therapeutic vaccine Vacc-4x prior to romidepsin The study confirms that Bionor’s proprietary peptide vaccine, Vacc-4x, is a safe and tolerated potential functional cure for HIV (Oslo, Norway, 4 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing …

Read more